GROWTHFORGE · BEACON · SOURCE-BACKED SIGNAL
Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma
NCT04752696 is on the Cheap-to-Truth Radar because its public ClinicalTrials.gov record contains a recent development signal worth inspecting. This page is not a recommendation or diligence conclusion.
Priority to inspect82/100
StatusTERMINATED
PhasePHASE2
Lead sponsorCardiff Oncology
Last update2026-11-04
Public-record facts
| Intervention | Onvansertib (DRUG), Nanoliposomal irinotecan (DRUG), Leucovorin (DRUG), Fluorouracil (DRUG) |
|---|---|
| Condition | Pancreatic Ductal Adenocarcinoma |
| Enrollment | 41 |
| Why stopped | Sponsor decision based on meeting essential enrollment and obtaining substantial data to support future pancreatic ductal adenocarcinoma (PDAC) trials in a first-line setting. |
| Results posted | Yes |
Why Beacon surfaced it
- The record is terminated and was updated 2026-11-04.
- It is an interventional PHASE2 study with a named drug/drug/drug/drug intervention.
- The lead sponsor is classified as industry.
- The record states a reason for stopping, creating a concrete diligence question.
- ClinicalTrials.gov indicates posted results are available.
What Cheap-to-Truth would verify next
- Was the stopping reason scientific, operational, financial, strategic, or mixed?
- What human safety and efficacy evidence actually exists beyond the registry summary?
- Who controls the relevant rights, and are they practically obtainable?
- Is there an indication and endpoint where a smaller experiment could answer the key decision?
- Would the resulting data be usable by the regulator that matters?
Source: ClinicalTrials.gov NCT04752696. Registry information is sponsor/investigator submitted; verify primary evidence before making development decisions.